|
1.
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3.
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S and
Chua YJ; MAGIC Trial Participants: Perioperative chemotherapy
versus surgery alone for resectable gastroesophageal cancer. N Engl
J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar
|
|
5.
|
Chollet P, Schöffski P, Weigang-Köhler K,
Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J
and Fumoleau P; EORTC Early Clinical Studies Group: Phase II trial
with S-1 in chemotherapy-naïve patients with gastric cancer. A
trial performed by the EORTC Early Clinical Studies Group (ECSG).
Eur J Cancer. 39:1264–1270. 2003.
|
|
6.
|
Koizumi W, Kurihara M, Nakano S and
Hasegawa K: Phase II study of S-1, a novel oral derivative of
5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative
Gastric Cancer Study Group. Oncology. 58:191–197. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi
K, Mitachi Y and Taguchi T: Late phase II study of novel oral
fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1
M otastat potassium) in advanced gastric cancer patients. Eur J
Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393.
2011.
|
|
9.
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Higuchi K, Koizumi W, Yamada Y, et al:
Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus
cisplatin for first-line treatment of advanced gastric cancer. J
Clin Oncol. 30(Suppl 34): abs. 60. 2012.
|
|
12.
|
Li J, Yin J, Zhu X, Liu Y, Cao J, Lu F and
Zuo Y: Phase I dose-escalating study of S-1 in combination with
oxaliplatin for patients with advanced and/or metastatic colorectal
cancer. Anticancer Drugs. 19:745–748. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yamada Y, Tahara M, Miya T, Satoh T,
Shirao K, Shimada Y, Ohtsu A, Sasaki Y and Tanigawara Y: Phase I/II
study of oxaliplatin with oral S-1 as first-line therapy for
patients with metastatic colorectal cancer. Br J Cancer.
98:1034–1038. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Park I, Lee JL, Ryu MH, et al: Phase I/II
and pharmacokinetic study of S-1 and oxaliplatin in previously
untreated advanced gastric cancer. Cancer Chemother Pharmacol.
65:473–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kim GM, Jeung HC, Rha SY, Kim HS, Jung I,
Nam BH, Lee KH and Chung HC: A randomized phase II trial of
S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric
cancer. Eur J Cancer. 48:518–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kodera Y, Ito S, Mochizuki Y, et al: Chubu
Clinical Oncology Group: A phase II study of radical surgery
followed by postoperative chemotherapy with S-1 for gastric
carcinoma with free cancer cells in the peritoneal cavity (CCOG0301
study). Eur J Surg Oncol. 35:1158–1163. 2009. View Article : Google Scholar
|
|
17.
|
Liu B, Ying J, Luo C, Xu Q, Zhu L and
Zhong H: S-1 combined with oxaliplatin as first line chemotherapy
for Chinese advanced gastric cancer patients.
Hepatogastroenterology. 59:649–653. 2012.PubMed/NCBI
|
|
18.
|
Yoshikawa T, Omura K, Kobayashi O,
Nashimoto A, Takabayashi A, Yamada T, Yamaue H, Fujii M, Yamaguchi
T and Nakajima T: A phase II study of preoperative chemotherapy
with S-1 plus cisplatin followed by D2/D3 gastrectomy for
clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur
J Surg Oncol. 36:546–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
El Sayed YM and Sadee W: Metabolic
activation of ftorafur
[R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal
oxidative pathway. Biochem Pharmacol. 31:3006–3008. 1982.
|
|
20.
|
Ikeda K, Yoshisue K, Matsushima E,
Nagayama S, Kobayashi K, Tyson CA, Chiba K and Kawaguchi Y:
Bioactivation of tegafur to 5-fluorouracil is catalyzed by
cytochrome P-450 2A6 in human liver microsomes in vitro. Clin
Cancer Res. 6:4409–4415. 2000.PubMed/NCBI
|
|
21.
|
Fujita K, Yamamoto W, Endo S, et al:
CYP2A6 and the plasma level of 5-chloro-2,4-dihydroxypyridine are
determinants of the pharmacokinetic variability of tegafur and
5-fluorouracil, respectively, in Japanese patients with cancer
given S-1. Cancer Sci. 99:1049–1054. 2008. View Article : Google Scholar
|
|
22.
|
Kim KP, Jang G, Hong YS, et al: Phase II
study of S-1 combined with oxaliplatin as therapy for patients with
metastatic biliary tract cancer: influence of the CYP2A6
polymorphism on pharmacokinetics and clinical activity. Br J
Cancer. 104:605–612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ariyoshi N, Sawamura Y and Kamataki T: A
novel single nucleotide polymorphism altering stability and
activity of CYP2a6. Biochem Biophys Res Commun. 281:810–814. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Xu C, Rao YS, Xu B, Hoffmann E, Jones J,
Sellers EM and Tyndale RF: An in vivo pilot study characterizing
the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun.
290:318–324. 2002.PubMed/NCBI
|
|
25.
|
Yoshida R, Nakajima M, Watanabe Y, Kwon JT
and Yokoi T: Genetic polymorphisms in human CYP2A6 gene causing
impaired nicotine metabolism. Br J Clin Pharmacol. 54:511–517.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Kim WY, Nakata B and Hirakawa K:
Alternative pharmacokinetics of S-1 components, 5-fluorouracil,
dihydrofluorouracil and alpha-fluoro-beta-alanine after oral
administration of S-1 following total gastrectomy. Cancer Sci.
98:1604–1608. 2007. View Article : Google Scholar
|
|
27.
|
Kochi M, Fujii M, Kanamori N, Kaiga T,
Aizaki K, Takahashi T and Takayama T: Effect of gastrectomy on the
pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable
gastric cancer patients. Cancer Chemother Pharmacol. 60:693–701.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kong SY, Lim HS, Nam BH, et al:
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy
outcomes in metastatic gastric cancer. Pharmacogenomics.
10:1147–1155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Park SR, Kong SY, Nam BH, et al: CYP2A6
and ERCC1 polymorphisms correlate with efficacy of S-1 plus
cisplatin in metastatic gastric cancer patients. Br J Cancer.
104:1126–1134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Christian K, Lang M, Maurel P and
Raffalli-Mathieu F: Interaction of heterogeneous nuclear
ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications
for post-transcriptional regulation of the CYP2A6 gene. Mol
Pharmacol. 65:1405–1414. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Raffalli-Mathieu F, Glisovic T, Ben-David
Y and Lang MA: Heterogeneous nuclear ribonucleoprotein A1 and
regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol.
61:795–799. 2002. View Article : Google Scholar : PubMed/NCBI
|
